SciSparc-Clearmind Collaboration Wins U.S. MDMA-PEA Patent

Regulatory affairs leads tracking psychedelic drug development now have two concurrent reference points: a finalized FDA guidance document and a newly published U.S. patent application from the NeuroThera-Clearmind collaboration covering an MDMA and N-acylethanolamines combination for PTSD, anxiety, and eating disorders.

The patent application, published by the United States Patent and Trademark Office, covers a novel combination of 3,4-methylenedioxymethamphetamine (MDMA) and N-acylethanolamines, specifically palmitoylethanolamide (PEA). The application includes embodiments addressing PEA's potential effects on MDMA's therapeutic potency, required dosing, side-effect profile, and therapeutic window. It brings the total number of published patent applications generated through the NeuroThera-Clearmind collaboration to thirteen globally.

The publication coincides with the FDA's July 14, 2026 finalization of its guidance, Psychedelic Drugs: Considerations for Clinical Investigations. The document explicitly classifies MDMA as a psychedelic drug, categorizing it alongside classic psychedelics as an entactogen or empathogen. For sponsors, the guidance addresses clinical trial design and conduct, data collection, subject safety protocols, and NDA submission requirements specific to psychedelic compounds.

The FDA acknowledges in the guidance that psychedelic drugs present distinct clinical development challenges due to their psychoactive effects and alterations in mood, cognition, and perception. Sponsors developing MDMA-based programs will need to account for these considerations when structuring study designs and preparing regulatory submissions, particularly around blinding methodology and safety monitoring frameworks.

For QA directors and regulatory leads at organizations with active CNS pipelines, the guidance establishes the FDA's current thinking on acceptable development pathways for this compound class, reducing some of the interpretive ambiguity that has historically complicated IND and NDA planning for psychedelic-derived therapeutics. The NeuroThera-Clearmind IP portfolio, now anchored by this U.S. application, positions the collaboration within that emerging regulatory framework.

NeuroThera Labs Inc., a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is a clinical-stage company focused on CNS disorders. Clearmind Medicine Inc. (Nasdaq: CMND) contributes psychedelic-derived therapeutic programs to the collaboration, with NeuroThera's PEA technology integrated into the joint development effort.

The next measurable checkpoint for sponsors in this space will be aligning existing or planned MDMA study protocols against the FDA's finalized guidance requirements ahead of any IND submissions.

Source: GlobeNewswire via SciSparc Ltd. press release, August 24, 2026.